Wird geladen...
Protective, repairing and fibrinolytic effects of rivaroxaban on vascular endothelium
AIMS: Rivaroxaban, a direct inhibitor of activated factor X (FXa), is the only new oral anticoagulant approved for secondary prevention after acute coronary syndrome. Our objective was to identify the possible molecular mechanisms of rivaroxaban that contribute to endothelial function. METHODS: Cell...
Gespeichert in:
| Veröffentlicht in: | Br J Clin Pharmacol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
John Wiley and Sons Inc.
2017
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5777430/ https://ncbi.nlm.nih.gov/pubmed/28940408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13440 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|